JANX Company Profile and Key Details

JANX has shown weak momentum, losing -2.27% over the past week and -43.54% over the past quarter, though year-to-date performance is down -74.22%. Short-term trend indicators are bullishly aligned (SMA20 -7.62%, SMA50 -40.05%, SMA200 -44.78%). The stock’s 14-day RSI is 27.57 (weak momentum), while the ATR of 1.16 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -77.59% below its high and over 0.29% above its low. Average 10-day trading volume of 1.72 million shares is in line with the 3-month average of 1.73 million, indicating normal recent market interest.

Janux Therapeutics, Inc. has 60.09 million shares outstanding. The public float is 44.97 million shares, elevated short interest at 21.29% of float. This equals 8.73 million shares. The short ratio is 10.83 days. Institutional investors hold 117.75% of the float. Insiders own 6.59%. RA CAPITAL MANAGEMENT, L.P. holds 10.14 million shares, Bregua Corp has 3.75 million shares and Reardon Tighe has 633.67 thousand shares. Over the past six months, insider transactions show net selling. They sold 20.63 thousand shares across 3 transactions.

Janux Therapeutics, Inc. generated EPS of -$1.68 over the past year. Five-year average earnings growth is -67.9%. The latest quarter delivered EPS of -$0.39. The next quarter is forecast at -$0.62. Next year's EPS is expected at -$13.64. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 9 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $200.00 to $41.00. The high target offers 1349.28% upside. The low target suggests 197.1% downside. The mean target is $68.88. This offers 399.13% upside. Janux Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -47.3%. The prior quarter beat by 14.58%. Over the last six quarters, Apple has recorded several small beats. These include -65.62% in August 07, 2024.

Janux Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.12. This means the shares are trading above this model’s fair value.

Janux Therapeutics, Inc. (NASDAQ:JANX) closed at $13.80 USD, losing -$0.03 (-0.22%) from the previous close of $13.83. The stock is currently within 5% of its 52-week low $13.62 and $61.59. With a market capitalization of about $830.03 million, Janux Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.81). Key stats such as the average daily volume over the past year has been around 1.85 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Janux Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Alan Campbell, the company employs approximately 91 people and listed since June 11, 2021. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.

Our AI price prediction model suggests that Janux Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -49.28%, with price expected at $7.00 by January 13, 2026, within a range of $1.64 to $12.67 3-Month Outlook: Projected fall of -84.06%, reaching $2.20 by March 30, 2026, with a range of $1.03 to $3.26. 1-Year Outlook: Projected loss of -35.22%, with price at $8.94 by December 30, 2026, within a range of $0.00 to $9.51.

Janux Therapeutics, Inc. (NASDAQ:JANX) shares are down -74.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Janux Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.33. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $70.71, suggesting 412.39% upside. Our AI forecast model points to short-term weakness (-49.28% over two weeks), a medium-term fall (-84.06% over three months), and a longer-term loss (-35.22% over one year), with expected trading ranges indicating moderate volatility.

Janux Therapeutics, Inc. trades at a P/E ratio of -8.33, slightly below the S&P 500 average, with a price-to-sales ratio of 552.96 and a price-to-book ratio of 0.87 suggesting the stock is closer to book value. The P/FCF stands at -11.52, also above market averages.